High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.

"Declarations Ethics approval and consent to participateEthical, legal, and social implications were approved by the Ethics Committee of Yamaguchi University Hospital (H20-102, H23-135, and H28-074). This study was conducted per the Helsinki Declaration for experimentation on human subjects. All the samples were obtained with informed consent from the patients. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This study was performed as part of a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT; 11039020) and The Japan Agency for Medical Research and Development (AMED; 15cm0106085h0005). This study was supported in part by a grant from the Japan Agency for Medical Research and Development for Leading Advanced Projects for Medical Innovation (LEAP; 16am0001006h0003)."